Cerecin

Cerecin (also styled Cerecin Neurosciences) is a healthcare company focused on brain health, describing itself as having more than 20 years of innovation and leadership in the field. It develops novel evidence-based therapeutics and products intended to help millions of people, targeting conditions that range from memory impairment to Alzheimer's disease and other devastating neurological diseases. Its stated mission is a world in which people are not burdened by neurological disease, and its vision is to create impact through medicines that treat, cure and prevent diseases of the brain. The company's scientific approach centers on neuro-metabolism: targeting the underlying metabolic dysfunction in neurological conditions. Changes in brain metabolism can manifest as cognitive impairment from neurodegenerative processes such as Alzheimer's disease and other dementias, or as increased neuronal excitability leading to seizures in children and adults, as well as headaches and migraine. Cerecin's lead investigational product, tricaprilin (CER-0001), is an oral drug believed to mimic ketosis after administration under normal dietary conditions. Ketone bodies are normally produced under low glucose availability, such as fasting or low carbohydrate intake, and function as an alternative to glucose; in many neurological conditions ketosis has been shown to provide benefit both as an alternate energy substrate and through signaling pathways. Cerecin is investigating whether tricaprilin, through exogenous induction of ketone bodies, can provide an alternative fuel source for metabolically compromised areas of the brain in Alzheimer's disease. Cerecin describes itself as a healthcare company with more than 20 years of innovation and leadership in brain health, and it pioneers the science of neuro-metabolism and ketogenic drug development. It states that, with a world-class team and strong strategic partners Nestlé and Wilmar, it has bold ambitions to develop a portfolio of first-in-class products that help millions of patients throughout the world. The company is described as a drug development company and as a subsidiary of Nestlé Health Science. It maintains offices in four countries — the United States, Singapore, Australia and South Korea — and has been active in the Korean biotech market, including appointing a Korean CFO and pursuing a KOSDAQ listing. Cerecin's pipeline and partnerships span rare pediatric epilepsy, infantile spasms, migraine and Alzheimer's disease. Its news record includes a publication of a clinical study of CER-0001 (tricaprilin) for rare pediatric epilepsy, participation in the NIHR HealthTech Research Centre in Brain Health as an industry partner, an MOU with Cha Bundang Hospital, expansion of its leadership team with a Chief Medical Officer and Chief Operating Officer, a strategic acquisition from Boston Scientific, a strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore, and presentations of infantile spasms and migraine data at international congresses. The company is led by President & CEO Charles Stacey, MD, a physician and former healthcare investor.

Cerecin is a healthcare company that describes itself as having more than 20 years of innovation and leadership in brain health. It pioneers the science of neuro-metabolism and ketogenic drug development, with the stated ambition — supported by strategic partners Nestlé and Wilmar — to develop a portfolio of first-in-class products that help millions of patients worldwide. The company is a drug development company and a subsidiary of Nestlé Health Science, and it maintains offices in four countries: the United States, Singapore, Australia and South Korea. Cerecin's scientific foundation is the targeting of underlying metabolic dysfunction in neurological conditions. Changes in brain metabolism can result in neurological disorders, manifesting as cognitive impairment due to neurodegenerative processes such as Alzheimer's disease and other dementias, or as increased excitability of neurons leading to seizures in children and adults, as well as headaches and migraine. The company's approach is the induction of ketosis: its lead investigational oral drug, tricaprilin (CER-0001), is believed to mimic ketosis after administration under normal dietary conditions. Ketone bodies are normally produced by the body under conditions of low glucose availability, such as fasting or low carbohydrate intake, and function as an alternative to glucose. In many neurological conditions, ketosis has been shown to benefit patients not only by providing an alternate energy substrate but also through signaling pathways. Cerecin is investigating whether tricaprilin, through exogenous induction of ketone bodies, can provide an alternative fuel source for metabolically compromised areas of the brain in Alzheimer's disease. In recent years Cerecin has expanded its pipeline and partnerships. In 2023 it strengthened its position in neurometabolism with an addition to its pipeline, presented new infantile spasms data at the 35th International Epilepsy Congress in Dublin, and reported clinical trial data on a novel metabolic mechanism in migraine for CER-0001, a ketogenic investigational agent. In December 2023 it forged a strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders. In January 2024 it bolstered its pipeline with a strategic acquisition from Boston Scientific. In September 2024 it expanded its leadership team with the appointment of a Chief Medical Officer and a Chief Operating Officer. In April 2025 it signed an MOU with Cha Bundang Hospital, and in August 2025 it joined the NIHR HealthTech Research Centre in Brain Health as an industry partner. In February 2026 it announced the publication of a clinical study demonstrating promising results of CER-0001 (tricaprilin) for rare pediatric epilepsy, and published commentary on the potential of fasting and diet in the future of medicine. Cerecin has also been active in the Korean biotech market. It has offices in South Korea and appointed a Korean CFO, and it pursued a KOSDAQ listing with Samsung Securities and Hana Securities as underwriters. In 2025, about four months after filing its listing preliminary review request, the Korea Exchange's KOSDAQ Market Listing Committee finalized the result of Cerecin's KOSDAQ listing preliminary review as 'not approved.' The company is led by President & CEO Charles Stacey, MD, who has over 20 years of experience in healthcare as a provider, executive, entrepreneur and investor; prior to joining Cerecin he was with Inventages, the Nestlé-backed venture capital and private equity group, where he led the CNS interest and the fund's interest in Asia.

• Clinical trial data of novel metabolic mechanism in migraine for CER-0001, a ketogenic investigational agent

• Cerecin to present new infantile spasms data at the 35th International Epilepsy Congress, Dublin 2023

• Cerecin strengthens position in neurometabolism with addition to pipeline

• Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders

• Cerecin bolsters pipeline with a strategic acquisition from Boston Scientific

• Cerecin expands leadership team with appointment of Chief Medical Officer and Chief Operating Officer

• Cerecin signs an MOU with Cha Bundang Hospital

• Cerecin joins NIHR HealthTech Research Centre in Brain Health as an industry partner

• Cerecin pursued a KOSDAQ listing with Samsung Securities and Hana Securities as underwriters; the KOSDAQ Market Listing Committee finalized the preliminary review result as 'not approved'

• The Potential of Fasting and Diet in the Future of Medicine

• Cerecin announces publication of clinical study demonstrating promising results of CER-0001 (tricaprilin) for rare pediatric epilepsy

Clinical-stage neuroscience drug developer pioneering neuro-metabolism and ketogenic drug development, backed by Nestlé Health Science and Wilmar.

• CER-0001 (tricaprilin)

  Investigational oral drug believed to mimic ketosis after administration under normal dietary conditions; being studied in Alzheimer's disease, migraine, rare pediatric epilepsy and infantile spasms.

1. 1Cerecin Neurosciencescerecin.com
2. 2Cerecin Neurosciences - About Uscerecin.com
3. 3Cerecin Neurosciences - Sciencecerecin.com
4. 4Cerecin - Wikidatawikidata.org
5. 5세레신 - Wikipedia (Korean)ko.wikipedia.org